Seer (SEER) Income from Continuing Operations (2020 - 2026)
Seer (SEER) recorded quarterly Income from Continuing Operations of 16837000.0 in Q1 2026, down 5.27% quarter-over-quarter from 15994000.0 in Q4 2025, and up 15.6% on a YoY basis from 14565439.78 in Q1 2025.
Seer (SEER) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Seer's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 16837000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 15.6% year-over-year to 16837000.0; the TTM figure through Mar 2026 stood at 70489000.0 (up 18.15% YoY), while the FY2025 annual figure was 73600000.0, up 15.25% from the prior year.
- Income from Continuing Operations was 16837000.0 for Q1 2026 at Seer, down from 15994000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 67546000.0 in Q4 2023 to a low of 23980000.0 in Q3 2022.
- Historically, Income from Continuing Operations has averaged 15951882.35 across 5 years, with a median of 21328000.0 in 2024.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations soared 399.87% in 2023, then tumbled 132.56% in 2024.
- A 5-year view of Income from Continuing Operations shows it stood at 22525000.0 in 2022, then jumped by 399.87% to 67546000.0 in 2023, then slumped by 132.56% to 21990000.0 in 2024, then climbed by 27.27% to 15994000.0 in 2025, then dropped by 5.27% to 16837000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 16837000.0 (Q1 2026), 15994000.0 (Q4 2025), and 18234000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Seer | 99.67 Mn | 99.67 Mn | 982,000.00 | -16.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.84 Mn |
| Dec 31, 2025 | -15.99 Mn |
| Sep 30, 2025 | -18.23 Mn |
| Jun 30, 2025 | -19.42 Mn |
| Mar 31, 2025 | -19.95 Mn |
| Dec 31, 2024 | -21.99 Mn |
| Sep 30, 2024 | -21.33 Mn |
| Jun 30, 2024 | -22.85 Mn |
| Mar 31, 2024 | -20.68 Mn |
| Dec 31, 2023 | 67.55 Mn |
| Sep 30, 2023 | -21.09 Mn |
| Jun 30, 2023 | -23.43 Mn |
| Mar 31, 2023 | -23.96 Mn |
| Dec 31, 2022 | -22.53 Mn |
| Sep 30, 2022 | -23.98 Mn |
| Jun 30, 2022 | -22.82 Mn |
| Mar 31, 2022 | -23.65 Mn |
| Dec 31, 2021 | -19.74 Mn |
| Sep 30, 2021 | -18.39 Mn |
| Jun 30, 2021 | -16.62 Mn |